Gilead Sciences, Inc. (NASDAQ:GILD) Position Increased by Hancock Whitney Corp

Hancock Whitney Corp lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 109,929 shares of the biopharmaceutical company’s stock after buying an additional 12,109 shares during the quarter. Hancock Whitney Corp’s holdings in Gilead Sciences were worth $8,905,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Jump Financial LLC acquired a new position in Gilead Sciences in the third quarter valued at approximately $222,000. Quantbot Technologies LP bought a new position in Gilead Sciences during the 3rd quarter worth $88,000. Campbell & CO Investment Adviser LLC acquired a new stake in Gilead Sciences in the third quarter worth $468,000. Alliance Wealth Advisors LLC UT boosted its holdings in shares of Gilead Sciences by 5.4% during the third quarter. Alliance Wealth Advisors LLC UT now owns 21,054 shares of the biopharmaceutical company’s stock valued at $1,578,000 after acquiring an additional 1,075 shares during the period. Finally, One Capital Management LLC bought a new position in shares of Gilead Sciences during the third quarter worth about $565,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Mizuho reduced their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Wells Fargo & Company decreased their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday, April 26th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Finally, Barclays cut their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Hold” and a consensus price target of $83.69.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.81 during trading on Tuesday, hitting $64.44. The company had a trading volume of 860,983 shares, compared to its average volume of 7,244,104. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The business’s 50-day moving average is $66.51 and its 200 day moving average is $73.62. The company has a market cap of $80.28 billion, a P/E ratio of 181.25, a PEG ratio of 1.29 and a beta of 0.20. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period in the previous year, the firm earned $1.37 earnings per share. Gilead Sciences’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.78%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.